141 related articles for article (PubMed ID: 38095304)
41. Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission.
Li Y; Dai H; Yao D; Gao X; Xue Y; Wang W
Ann Hematol; 2022 Aug; 101(8):1865-1867. PubMed ID: 35347396
[No Abstract] [Full Text] [Related]
42. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
43. Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
Lucijanic M; Tomasovic-Loncaric C; Stoos-Veic T; De Both T; Jalsenjak B; Kusec R
Ann Hematol; 2024 Feb; 103(2):671-672. PubMed ID: 37946030
[No Abstract] [Full Text] [Related]
44. BCL-2 inhibition in AML: an unexpected bonus?
Konopleva M; Letai A
Blood; 2018 Sep; 132(10):1007-1012. PubMed ID: 30037885
[TBL] [Abstract][Full Text] [Related]
45. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
46. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
[TBL] [Abstract][Full Text] [Related]
47. Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
Taniguchi S; Yamauchi T; Choi I; Fukuhara N; Potluri J; Salem AH; Hong WJ; Honda H; Nishimura Y; Okubo S; Usuki K
Jpn J Clin Oncol; 2021 May; 51(6):857-864. PubMed ID: 33712849
[TBL] [Abstract][Full Text] [Related]
48. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine.
Islam N; Reuben JS; Dale J; Gutman J; McMahon CM; Amaya M; Goodman B; Toninato J; Gasparetto M; Stevens B; Pei S; Gillen A; Staggs S; Engel K; Davis S; Hull M; Burke E; Larchick L; Zane R; Weller G; Jordan C; Smith C
JCO Clin Cancer Inform; 2022 Sep; 6():e2200030. PubMed ID: 36194842
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
Patel KK; Zeidan AM; Shallis RM; Prebet T; Podoltsev N; Huntington SF
Blood Adv; 2021 Feb; 5(4):994-1002. PubMed ID: 33591323
[TBL] [Abstract][Full Text] [Related]
50. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
Pollyea DA; Pratz KW; Wei AH; Pullarkat V; Jonas BA; Recher C; Babu S; Schuh AC; Dail M; Sun Y; Potluri J; Chyla B; DiNardo CD
Clin Cancer Res; 2022 Dec; 28(24):5272-5279. PubMed ID: 36007102
[TBL] [Abstract][Full Text] [Related]
51. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
[TBL] [Abstract][Full Text] [Related]
52. Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Wang H; Bai J; Pei Z; Zhang B; Wang J; Lian X; Song Q
Medicine (Baltimore); 2020 Nov; 99(47):e23265. PubMed ID: 33217852
[TBL] [Abstract][Full Text] [Related]
53. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
[TBL] [Abstract][Full Text] [Related]
54. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
55. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Winters AC; Bosma G; Abbott D; Minhajuddin M; Jordan C; Pollyea DA; Gutman JA
Transplant Cell Ther; 2022 Oct; 28(10):694.e1-694.e9. PubMed ID: 35902048
[TBL] [Abstract][Full Text] [Related]
56. Azacitidine and Venetoclax in AML.
Moore JW; Pelcovits A; Reagan JL
N Engl J Med; 2020 Nov; 383(21):2088. PubMed ID: 33207105
[No Abstract] [Full Text] [Related]
57. Azacitidine and Venetoclax in AML.
Lucijanic M
N Engl J Med; 2020 Nov; 383(21):2087-2088. PubMed ID: 33207104
[No Abstract] [Full Text] [Related]
58. Azacitidine and Venetoclax in AML.
Chitikela S; Kumar L; Sahoo RK
N Engl J Med; 2020 Nov; 383(21):2087. PubMed ID: 33207103
[No Abstract] [Full Text] [Related]
59. Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
Yasu T; Gando Y; Shirota M; Kosugi N; Kobayashi M
Leuk Lymphoma; 2024 Jan; 65(1):128-131. PubMed ID: 37797220
[No Abstract] [Full Text] [Related]
60. Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
Naka R; Kondo T; Nishikubo M; Muranushi H; Ueda Y; Oka T; Wada F; Kanda J; Yamamoto S; Watanabe M; Okada S; Imada K; Nakabo Y; Mizutani Y; Nannya Y; Ogawa S; Ishikawa T
Am J Hematol; 2023 Sep; 98(9):E251-E254. PubMed ID: 37381699
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]